Fan Site: Inspired, Not Endorsed, By Rakesh Jhunjhunwala

Posts tagged Cadila Healthcare

Daljeet Kohli Stock Pick Cadila Healthcare Surges



Daljeet Kohli of IndiaNivesh has mastered the art of homing in on stocks just before they perk up. Apart from Alembic and J. B. Chemical, Cadila is another example of this splendid stock selection

Check Out Daljeet Kohli’s Latest Pharma Stock Pick: Cadila Healthcare



Daljeet Kohli of IndiaNivesh is obviously buoyed by the success of his earlier two stock picks, Alembic Pharma & J. B. Chem. Both stocks have given hefty returns and are still looking good for more gains. His latest stock pick, Cadila Healthcare, has been an under-performer so far. However, a re-rating is on the cards for Cadila and there will be a 20% gain, says Daljeet confidently

Newer Entries →

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 493 other subscribers

RSS Stocks Talk Forum

  • Top Picks Basket of 16 Stocks (8 Large-Cap, 5 Mid-Cap & 3 Small-Cap)
    Top Picks Basket of 16 Stocks (8 Large-Cap, 5 Mid-Cap & 3 Small-Cap) for Nov '24. The Basket has delivered return of 329% since inception (May’20) vs 162% return delivered by NIFTY Index over the same period due to thematic approach to Top Picks selection Download report
  • Shalby is a multi-specialty hospital chain with expertise in joint replacement
    Shalby is a multi-specialty hospital chain with expertise in joint replacement. It is making right strides with calibrated growth based on big ticket expansion in metros & tier I cities & asset-light franchisee expansion in tier II-VI towns. TP ₹310 (35%) Download... Shalby is a multi-specialty hospital chain with expertise in joint replacement
  • DLF has strong growth prospects. Buy for target price of ₹1081 (30% upside)
    DLF has strong growth prospects due to strong sectoral tailwinds, record low inventory, greater preference for branded luxury, extensive launch pipeline & expansion in its annuity portfolio. Strong Balance Sheet with consistent cash flow. TP ₹1081 (+30%) Research Report... DLF has strong growth prospects. Buy for target price of ₹1081 (30% upside)
Disclaimer: This is a Fan Site in Rakesh Jhunjhunwala's name. Rakesh Jhunjhunwala is not associated with us and is in no way aware, accountable or responsible for what is stated here. Further, nothing here constiutes investment advice for you to act on. Also, we have a vested interest, and are extremely biased, in everything that we say. So Mind It!